XRF-1021
XRF-1021 is an orally active HIPK2 inhibitor (IC50 = 0.18 μM) . XRF-1021 reduces the expression of fibrotic markers in TGF-β1 stimulated NRK-49F and HK-2 cells, including Fibronectin, Collagen I and α-SMA. XRF-1021 blocks TGF-β, NF-κB, p53, Wnt/β-catenin, and Notch signaling. XRF-1021 reduces renal injury and fibrosis in vivo. XRF-1021 can be used for the research of chronic kidney disease[1].
Product Specifications
CAS Number
2968523-32-0
UNSPSC
12352005
Target
DYRK; MDM-2/p53; NF-κB; Notch; TGF-beta/Smad; Wnt; β-catenin
Related Pathways
Apoptosis; Neuronal Signaling; NF-κB; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; TGF-beta/Smad
Field of Research
Inflammation/Immunology
Smiles
NC1=NC2=CC=CC=C2N1C3=NC=C(F)C(NC4=CC=C(N5CCNCC5)C=C4)=N3
Molecular Formula
C21H21FN8
Molecular Weight
404.44
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HIPK; NF-κB
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
PADI2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV)